From billion-dollar AI ventures to overlooked medicines and unconventional founders, Season 3 explored the science, investment decisions and human stories behind biotech innovation.
What does it take to build a successful biotech company? A groundbreaking idea, deep-pocketed investors, the right team, or simply the determination to keep going when the odds are stacked against you?
Season 3 of Raising Biotech explored these questions through six very different stories spanning AI, autoimmune disease, reproductive medicine, dermatology and biotech investing. A common theme emerged: success depends on much more than science. It takes timing, conviction, strategic decisions and, above all, the right people.
Big ambitions and billion-dollar bets
We opened with Xaira Therapeutics, which emerged from stealth in 2024 with more than $1 billion in financing and a mission to transform drug discovery through AI. Vik Bajaj, CEO and co-founder of Foresite Labs, explained why building it required a different approach to incubation: rather than applying AI to existing datasets, Xaira was designed to generate its own data, develop computational tools and build experimental capabilities in parallel. The question for the industry is whether AI can meaningfully change how medicines are discovered, or whether the real test comes when these platforms produce clinical results.
The people behind the capital
In one of the season’s more personal conversations, we explored the nearly 20-year partnership between serial entrepreneur Steve Butts and investor Dave Adair, who have built ten companies together through setbacks, successes and changing markets. Their latest venture, Arrivo BioVentures, was pursuing a treatment for depression in women, an underserved area. Their story highlighted the value of trust and long-term relationships between entrepreneurs and investors.
Second chances for overlooked science
AltruBio, led by CEO Dr Judy Chou, came out of a troubled corporate history that had brought the business close to bankruptcy. Its pipeline was rooted in decades of immunology research, but it needed a new strategy and leadership as well as fresh financing. By the time we spoke, it had closed a $225 million Series B, a dramatic turnaround.
Switzerland’s ReproNovo pursued a different kind of revival: finding overlooked or abandoned pharmaceutical assets and applying them to reproductive medicine. CEO Jean Marie Duval described programs in male infertility, embryo implantation and adenomyosis, backed by a $65 million Series A. Both stories challenged the assumption that innovation must begin with an entirely new molecule. Sometimes the opportunity lies in science others have left behind.
Taking the pulse of European biotech
Season 3 also took us to BIO-Europe 2025 in Vienna, where we gauged the mood among executives, investors and dealmakers navigating a challenging financing environment. The conversations captured cautious optimism alongside the practical realities of fundraising and partnering, a reminder that even the best science operates within a broader financial ecosystem.
Finding opportunity in underserved markets
Pattern hair loss is familiar to millions of people but has historically been underserved by pharmaceutical innovation. Veradermics, founded by dermatologist Dr Reid Waldman, was developing an extended-release oral minoxidil and, following a $150 million Series C, advancing its clinical program. Julie Hoggatt of InThought joined us for an independent view of the clinical data, competitive landscape and commercial considerations, underscoring the importance of evidence and differentiation.
Season 3 reinforced something we’ve explored since launching Raising Biotech: the journey from promising science to meaningful medical innovation is rarely linear. That’s what makes these stories worth telling.
Explore all six episodes of Raising Biotech Season 3 and subscribe wherever you listen to podcasts.